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METHODS 
Production of recombinant  JCV LTA: To produce recombinant JCV LTA, the glutathione S-transferase  
(GST) fusion protein of the intronless JCV large T antigen (pGEX1-LTA)was been obtained from Dr Kamel 
 Khalili at Temple University, Philadelphia. Ten-milliliter overnight cultures of Escherichia coli BL21 
 (E. coli B. F-, ompT, hsdS, gal, dcm) transformed with pGEX1λ-LTA were diluted 1:10 in fresh YT (2x) 
 medium supplemented with ampicillin (100 mg/ml). Cultures were induced with 1mM isopropyl-b- 
thiogalactopyranoside (IPTG) at an optical density of 0.6 and incubated overnight at 37°C. 
 Cells were collected by centrifugation and resuspended in 10ml of CelLytic B per gram of cell paste,  
supplemented with 0.2 mg/ml of lysozyme, 50 units/ml of benzonase, 1 M phenylmethylsulfonyl fluoride, 
 and protease inhibitor cocktail (Sigma-Aldrich). After incubating the extraction suspension 20 min with  
shaking at room temperature, clear cell lysates were prepared by centrifugation at 12,000g for 10 min. 
 Soluble and insoluble fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel  
electrophoresis (SDS-PAGE) followed by Coomassie blue staining. 
High throughput screening for inhibitors of ATPase activity: Inhibitor of ATPase activity was assessed by 
 the malachite green assay in which binding of molybdate and free phosphate produces a color change. 
 The Km for ATP was determined and the assay was optimized for buffer components  including, NaCl, MgCl2, 
 MnCl2, pH, detergent, and DTT. Then the linear range of the assay for different  enzyme concentrations  
was determined in order to select an enzyme concentration within the linear range when the ATP concentration 
was at the Km.   
 
CONCLUSIONS: LTA is a valid target for discovery of anti-JCV drugs. The  
hits identified are reasonable starting points for medicinal chemistry to improve  
potency and selectivity.  Screening of additional chemical libraries could  
also be considered to identify chemical structures that may be more 
 potent with acceptable cytotoxicity.  
ABSTRACT:  
Introduction: There are currently no JCV-specific therapies available for clinical use. This study 
evaluates viral large T antigen (LTA) as a potential target for drug development. LTA is a hexameric 
protein with a helicase activity that is powered by ATP binding and hydrolysis.  The helicase and 
ATPase function is critical for viral replication and inhibition by small molecules would disrupt the viral 
life cycle.  
Methods: Recombinant JCV LTA was produced in Escherichia coli using a plasmid from Dr. K.Khalili. 
ATPase activity was measured using the malachite green assay.  The Km for ATP was determined 
(80nM) and the assay optimized for buffer components.  A high throughput screen was completed 
using LDDN brain-biased compound library of 75,000 compounds.  The compounds in the library 
were selected with filters for drug-like properties and physicochemical properties consistent with 
blood brain barrier permeability.   
Results: Five compounds showed non-competitive inhibition of ATPase with an EC50≤10µM. Modest 
antiviral activity was demonstrated in an immunofluorescence assay for JCV VP-1 expression in 
COS7 cells (EC50 15.1, 18.1, 20.0, 26.6, and 52.5 µm respectively).  IC50 in the MTS96 and Cell 
TiterGlo assays was >100µM for all compounds in COS7 as well as HEK293 cells. However, two 
compounds inhibited cell proliferation in culture with IC50 values of 42.9 and 34.2 µM respectively. 
Three compounds inhibited viral replication in a real time PCR assay at concentrations between 10 
and 100 µM, but cell replication was also proportionally affected.   
Conclusion: LTA is a valid target for discovery of anti-JCV drugs. The hits identified can be starting 
points for medicinal chemistry to improve potency & selectivity.  Screening of more libraries could 
also be considered to identify compounds that may be more potent with acceptable cytotoxicity.  RESULTS: The Km for ATP was determined and the assay was optimized for buffer 
components including magnesium, manganese, DTT, MOPS, and pH (Figures 1, 2) 
 
 
 
 
 
 
 
 
 
Figure 1: Km for ATP was 73,3 µM. The  Figure 2: Reproducibility of the assay was satisfactory 
optimum buffer composition was 100mM MOPS,                            with a Z-factor of 0.76. 
 5 mM MgCl2, 250uM DTT, pH 7.0. 
 
The most cost-effective LTA concentration and the optimal reaction time were determined 
(Figure 3).  It was also ascertained that the ATPase assay was not sensitive to DTT at  
 
 
 
 
 
 
          
         Figure 3: Time kinetics of inorganic phosphate  
          release at different concentrations of LTA enzyme. 
          The X-axis depicts time in minutes. The Y-axis  
          plots the A620 nm of the reaction of phosphate 
         with malachite green. 
 
concentrations of up to 1200 µM and Brij concentrations of 0.1%. Five compounds LDN-
0012723, 0015182, 0063710, 0060230 and 0065780 showed non-competitive inhibition of 
ATPase with an IC50≤10µM (Table 1).  Modest antiviral activity was demonstrated in an 
immunofluorescence assay for JCV VP-1 expression in COS7 cells (IC50 18.1±8.2, 
15.1±4.1, 52.5±17.7, 19.9±6.1, 26.5±16.3 µM respectively, expressed as mean ± 
SD)(see Table 2).  However, LDN-0012723  and  LDN-0015182 also inhibited cell 
proliferation with IC50 values of 42.9.1±2.6,  and 34.2±8.2 respectively.  Hence, the 
selectivity index of the anti-viral effect was low (SI= 2.4 and 2.3 respectively). The 
remaining three compounds did not inhibit cell proliferation at concentrations up to 50 µM. 
In toxicity assays not dependent on cell proliferation, namely the MTS96 aqueous and Cell 
TiterGlo assays, the IC50 was >100µM for all compounds in COS7 as well as HEK293 
cells. Representative data is presented in for one compound in Figures 4 and 5.  In 
quantitative real time PCR based assays designed to directly measure viral replication in 
COS7 and POJ cells,  LDN-0063710 and LDN-0065780 showed no biologic activity, while 
the remaining three  compounds inhibited viral and host cell replication proportionally at 
concentrations between 10 and 100 µM (data not shown).  
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INTRODUCTION: We hypothesize that JCV inhibitory and glial protective  drugs can be discovered by  
screening chemical libraries for compounds that can inhibit the helicase machinery associated with JCV large 
 T antigen (LTA). LTA is good target for drug discovery because  (a) it is a key viral protein required for DNA  
replication, (b) it is well conserved across multiple viral strains, and (c) there is no homologous protein present 
in human cells, which offers of the prospect of developing anti-viral compounds with an acceptable toxicity 
 profile. LTA directs the initiation of viral DNA replication by assembly into a double hexameric helicase which  
unwinds the duplex DNA bidirectionally. The initial step is a binding of LTA to the origin binding domain on the 
viral regulatory region. The progression of viral replication requires the recruitment of several cellular factors  
including human replication protein A (hRPA), DNA polymerase alpha-primase, and DNA polymerase delta.  
These biochemical changes are energy dependent, and an ATPase domain as well as an ATP binding site are 
 present in the LTA protein.  Hence, it is reasonable to expect that small molecule  inhibitors of LTA   ATPase 
 and helicase activity will be detrimental to viral replication. Since, JCV replication  caused oligodendroglial  
degeneration in PML, anti-JCV small molecules will have a protective effect on glial cells in this disease. The 
 ATPase based assay described here is quite suited for high throughput screening, since it is a ‘mix and  
measure’ assay that requires only the addition of reagents. No extraction, centrifugation, or filtration steps 
 are involved. 
The assay was then miniaturized to 384-well plate format and automated for high 
throughput screening.  The LDDN brain-biased small molecule library of 75,000 compounds 
was used for HTS.  The compounds in the library were selected with filters to conform to 
Lipinski-type parameters but also to have the physicochemical properties to be more likely 
to cross the blood brain barrier.   
Q-PCR Assay for Measuring JCV Replication:  Real time PCR was used to directly 
measure JCV replication in Cos-7 cells. Simultaneous quantitation of a housekeeping gene 
ribosomal protein 32 (RPL32) sequence allowed monitoring of host cell replication. A 50% 
effective drug concentration (EC50), a 50% inhibitory (toxic) concentration (CC50), and the 
selectivity index (SI) were determined by standard methodology. The primers and probes 
used in this assay are directed to JCV VP-1 protein. 
Fluorescent Focus Assays for Measuring JCV VP-1 Gene Expression: Seventy percent 
confluent Cos-7 cells in tissue culture plates with coverslips were infected with JCV Mad-4 
stock for 4 days at 37C. Cells were fixed with 50% methanol-50% acetone for 10 min at 
room temperature, air dried for 15 min, and incubated for 1 hour at 37°C with anti-VP-1 
antibodies in PBS, followed by fluorescein isothiocyanate-conjugated anti-mouse 
immunoglobulin G secondary antibody. Quantitation of the percent of cells expressing viral 
antigens was performed using an in-house whole slide image analysis system. Drug 
concentrations effecting 50% reduction in VP-1 positive cells and total cell nuclei were 
respectively used to calculate EC50 and IC50. 
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Figure 4:  Effect of LDN 0015182 on JCV VP-1 expression expressed as a percentage of 
expression seen in cells not treated with drug.  Error bars smaller than the width of the line graph 
are not visible. 
Table 1: ATPase Inhibitory Actibity of Selected Compounds 
EC50 (M)
LDN# ATPase COS cells HEK cells
LDN-0012723 0.8 93.8 71.8
LDN-0015182 4 >100 >100
LDN-0063710 5 >100 >100
LDN-0060230 10 >100 >100
LDN-0065780 15 >100 >100
LD50 (M) 6 day
Table 2: Antiviral Activity of Selected Compounds 
In Immunofluorescence Assay (mean +/- sd) 
  IC50 µM EC50 µM SI 
LDN-0012723 42.9 ± 2.6 18.1 ± 8.2 2.4 
LDN-0015182 34.2 ± 8.2 15.1 ± 4.1 2.3 
LDN-0060230 >50 20 ± 6.2 >2.5 
LDN-0063710 >50 52.5 ± 17.7 >0.95 
LDN-0065780 >50 26.6 ± 16.3 >1.9 
Figure 5. JCV VP-1 expression in Cos7 cells with (right 
panels) or without (left panels) exposure to 30 µM LDN 
0015182.  Image analysis was done to quantify the 
percentage inhibition of signal captured  from the entire cover 
slip (upper panels). Higher magnification images (lower 
panels) illustrate that VP-1 staining had an exclusively 
nuclear localization. 
